DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape.
Amyotrophic Lateral Sclerosis Pipeline landscape is provided which includes the disease overview and Amyotrophic Lateral Sclerosis treatment guidelines. The assessment part of the Amyotrophic Lateral Sclerosis pipeline report embraces, in depth Amyotrophic Lateral Sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the Amyotrophic Lateral Sclerosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
- DelveInsight’s Amyotrophic Lateral Sclerosis Pipeline analysis depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
- Leading Amyotrophic Lateral Sclerosis Companies such as Biogen, Ionis Pharmaceuticals, Cytokinetics, AB Sciences, Alexion Pharmaceuticals, Orion Pharma, Orphazyme, Brainstorm-Cell Therapeutics, Amylyx Pharmaceuticals, Medicinova, Procypra Therapeutics, Biohaven Pharmaceuticals, Clene Nanomedicine, and others are evaluating new Amyotrophic Lateral Sclerosis pipeline to improve the treatment therapies.
- The promising Amyotrophic Lateral Sclerosis therapies such as AMX0035, BIIB067, Masitinib, Ravulizumab, Autologous MSC-NTF cells, and many others
- AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO), which were combined in a co-formulation to reduce neuronal death and dysfunction. AMX0035 was specifically co-formulated and manufactured by Amylyx to ensure proper absorption, exposure, and quality. AMX0035 targets endoplasmic reticulum and mitochondrial dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. The company has submitted a New Drug Submission (NDS) to Health Canada for AMX0035 (sodium phenylbutyrate (PB)-taurursodiol (TURSO)) for the treatment of ALS.
- BIIB067 (tofersen) is thought to reduce the production of SOD1 protein and is being evaluated in Phase III clinical trial to see if it can potentially slow the fatal progression of SOD1-ALS. Tofersen (BIIB067) previously called IONIS-SOD1Rx is an investigational therapy to slow the progression of familial Amyotrophic Lateral Sclerosis (ALS) (ALS). The therapy was developed in a collaboration between Ionis Pharmaceuticals and Biogen but is now being developed solely by Biogen.
Request a sample and discover the recent advances in Amyotrophic Lateral Sclerosis @ Amyotrophic Lateral Sclerosis Pipeline Outlook
Amyotrophic Lateral Sclerosis Overview
Amyotrophic Lateral Sclerosis (ALS) (ALS) is a rare neurological disease that primarily affects the nerve cells (neurons) responsible for controlling voluntary muscle movement (those muscles we choose to move). Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. ALS belongs to a wider group of disorders known as motor neuron diseases, which are caused by gradual deterioration (degeneration) and death of motor neurons.
Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. As motor neurons degenerate, they stop sending messages to the muscles and the muscles gradually weaken, start to twitch, and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. Early symptoms of ALS usually include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and individuals lose their strength and the ability to speak, eat, move, and even breathe. Most people with ALS die from respiratory failure, usually within 3 to 5 years from when the symptoms first appear. However, about 10 percent of people with ALS survive for 10 or more years.
Latest Breakthroughs and Developments in the Amyotrophic Lateral Sclerosis Treatment Landscape
- Amylyx Pharmaceuticals Inc. announced today the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting to review the Company’s New Drug Application for AMX0035 (sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
- Biogen Inc and Ionis Pharmaceuticals, Inc today announced topline results from the Phase 1 study of BIIB078 an investigational antisense oligonucleotide for people with C9orf72-associated amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis Pipeline Insight
Amyotrophic Lateral Sclerosis Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Amyotrophic Lateral Sclerosis (ALS) pipeline landscape is provided which includes the disease overview and Amyotrophic Lateral Sclerosis (ALS) treatment guidelines. The assessment part of the report embraces, in depth Amyotrophic Lateral Sclerosis (ALS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis (ALS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Amyotrophic Lateral Sclerosis Emerging Drugs
- AMX0035: Amylyx Pharmaceuticals
- BIIB067: Biogen
- Masitinib: AB Sciences
- Ravulizumab: Alexion Pharmaceuticals
- Autologous MSC-NTF cells: BrainStorm Cell Therapeutics
Amyotrophic Lateral Sclerosis Pipeline Analysis Report
- The report provides detailed insights about emerging therapies for the Amyotrophic Lateral Sclerosis treatment and the aggregate therapies developed by major pharma companies.
- It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
- It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- The Amyotrophic Lateral Sclerosis Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Amyotrophic Lateral Sclerosis market.
The Amyotrophic Lateral Sclerosis Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of the Amyotrophic Lateral Sclerosis Pipeline Report
Coverage- Global
Amyotrophic Lateral Sclerosis Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Amyotrophic Lateral Sclerosis Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Amyotrophic Lateral Sclerosis Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Amyotrophic Lateral Sclerosis Companies- Biogen, Ionis Pharmaceuticals, Cytokinetics, AB Sciences, Alexion Pharmaceuticals, Orion Pharma, Orphazyme, Brainstorm-Cell Therapeutics, Amylyx Pharmaceuticals, Medicinova, Procypra Therapeutics, Biohaven Pharmaceuticals, Clene Nanomedicine, and others
Amyotrophic Lateral Sclerosis therapies- AMX0035, BIIB067, Masitinib, Ravulizumab, Autologous MSC-NTF cells, and many others
Dive deep into rich insights for Amyotrophic Lateral Sclerosis Pipeline Assessment, Visit @ Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment
Table of Content
- Introduction
- Executive Summary
- Amyotrophic Lateral Sclerosis (ALS): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Preregistration)
- AMX0035: Amylyx Pharmaceuticals
- Mid Stage Products (Phase II)
- Early stage products (Phase I/II)
- Q-cells: Q therapeutics
- Inactive Products
- Amyotrophic Lateral Sclerosis (ALS) Key Companies
- Amyotrophic Lateral Sclerosis (ALS) Key Products
- Amyotrophic Lateral Sclerosis (ALS)- Unmet Needs
- Amyotrophic Lateral Sclerosis (ALS)- Market Drivers and Barriers
- Amyotrophic Lateral Sclerosis (ALS)- Future Perspectives and Conclusion
- Amyotrophic Lateral Sclerosis (ALS) Analyst Views
- Amyotrophic Lateral Sclerosis (ALS) Key Companies
- Appendix
For further information on the Amyotrophic Lateral Sclerosis Pipeline therapeutics, reach out @ Amyotrophic Lateral Sclerosis Drugs
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/